用环磷酰胺（60mg/m²）治疗晚期或转移性经预处理肺癌的II期试验
[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
作者信息
Rebattu P, Coudert B, Schneider M, Ouabdesselam R, Lentz M, Hanauske A, Chevallierdagger B, Fumoleau P, Chollet P
机构信息
Centre Léon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France.
出版信息
Rev Pneumol Clin. 2000 Jun;56(3):200-3.
PMID:10880946
Abstract
From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).
摘要
1990年1月至1994年11月，23例经前期治疗的晚期肺癌患者被纳入一项II期试验，以测试一种新的亚硝基脲——西司莫司汀，每2周静脉输注给药一次，剂量为60mg/m²，输注时间为15分钟。所有符合条件的患者均根据疗效和毒性（世界卫生组织标准）进行评估。
Zotero 插件